These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 23326337)

  • 21. The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study.
    McDonald CM; Henricson EK; Abresch RT; Florence J; Eagle M; Gappmaier E; Glanzman AM; ; Spiegel R; Barth J; Elfring G; Reha A; Peltz SW
    Muscle Nerve; 2013 Sep; 48(3):357-68. PubMed ID: 23674289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deflazacort versus prednisone/prednisolone for maintaining motor function and delaying loss of ambulation: A post HOC analysis from the ACT DMD trial.
    Shieh PB; Mcintosh J; Jin F; Souza M; Elfring G; Narayanan S; Trifillis P; Peltz SW; Mcdonald CM; Darras BT;
    Muscle Nerve; 2018 Nov; 58(5):639-645. PubMed ID: 30028519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids.
    Goemans N; van den Hauwe M; Wilson R; van Impe A; Klingels K; Buyse G
    Neuromuscul Disord; 2013 Aug; 23(8):618-23. PubMed ID: 23770101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strong correlation between the 6-minute walk test and accelerometry functional outcomes in boys with Duchenne muscular dystrophy.
    Davidson ZE; Ryan MM; Kornberg AJ; Walker KZ; Truby H
    J Child Neurol; 2015 Mar; 30(3):357-63. PubMed ID: 24762862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy.
    Mendell JR; Goemans N; Lowes LP; Alfano LN; Berry K; Shao J; Kaye EM; Mercuri E;
    Ann Neurol; 2016 Feb; 79(2):257-71. PubMed ID: 26573217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Longitudinal timed function tests in Duchenne muscular dystrophy: ImagingDMD cohort natural history.
    Arora H; Willcocks RJ; Lott DJ; Harrington AT; Senesac CR; Zilke KL; Daniels MJ; Xu D; Tennekoon GI; Finanger EL; Russman BS; Finkel RS; Triplett WT; Byrne BJ; Walter GA; Sweeney HL; Vandenborne K
    Muscle Nerve; 2018 Nov; 58(5):631-638. PubMed ID: 29742798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy.
    Mayhew AG; Cano SJ; Scott E; Eagle M; Bushby K; Manzur A; Muntoni F;
    Dev Med Child Neurol; 2013 Nov; 55(11):1046-52. PubMed ID: 23909763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Corticosteroids in Duchenne muscular dystrophy: a reappraisal.
    Wong BL; Christopher C
    J Child Neurol; 2002 Mar; 17(3):183-90. PubMed ID: 12026233
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy.
    Angelini C; Peterle E
    Acta Myol; 2012 May; 31(1):9-15. PubMed ID: 22655511
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Association Between Physical Activity/Heart Rate Variability Data Obtained Using a Wearable Device and Timed Motor Functional Tests in Patients with Duchenne Muscular Dystrophy: A Pilot Study.
    Nakamura A; Matsumura T; Takeshima Y; Kuru S; Imazaki M; Nonomura H; Kaiya H
    J Neuromuscul Dis; 2024; 11(3):715-724. PubMed ID: 38607760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single, large care center.
    Marden JR; Freimark J; Yao Z; Signorovitch J; Tian C; Wong BL
    J Comp Eff Res; 2020 Feb; 9(3):177-189. PubMed ID: 31922454
    [No Abstract]   [Full Text] [Related]  

  • 34. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
    Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
    PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of motor proficiency and functional ambulation in Duchenne muscular dystrophy with healthy peers.
    Yildiz S; Sahin S; Bulut N; Tunca Yilmaz O; Karaduman AA; Akel BS
    Somatosens Mot Res; 2020 Dec; 37(4):252-256. PubMed ID: 32583706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative muscle strength assessment in duchenne muscular dystrophy: longitudinal study and correlation with functional measures.
    Lerario A; Bonfiglio S; Sormani M; Tettamanti A; Marktel S; Napolitano S; Previtali S; Scarlato M; Natali-Sora M; Mercuri E; Bresolin N; Mongini T; Comi G; Gatti R; Ciceri F; Cossu G; Torrente Y
    BMC Neurol; 2012 Sep; 12():91. PubMed ID: 22974002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peak functional ability and age at loss of ambulation in Duchenne muscular dystrophy.
    Zambon AA; Ayyar Gupta V; Ridout D; Manzur AY; Baranello G; Trucco F; Muntoni F;
    Dev Med Child Neurol; 2022 Aug; 64(8):979-988. PubMed ID: 35385138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of Loss of Ambulation in Duchenne Muscular Dystrophy: A Systematic Review and Meta-Analysis.
    Landfeldt E; Alemán A; Abner S; Zhang R; Werner C; Tomazos I; Ferizovic N; Lochmüller H; Kirschner J
    J Neuromuscul Dis; 2024; 11(3):579-612. PubMed ID: 38669554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Age-related longitudinal changes in metabolic energy expenditure during walking in boys with Duchenne muscular dystrophy.
    Brehm MA; Kempen JC; van der Kooi AJ; de Groot IJ; van den Bergen JC; Verschuuren JJ; Niks EH; Harlaar J
    PLoS One; 2014; 9(12):e115200. PubMed ID: 25506914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy.
    Mayhew A; Cano S; Scott E; Eagle M; Bushby K; Muntoni F;
    Dev Med Child Neurol; 2011 Jun; 53(6):535-42. PubMed ID: 21410696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.